Aug 16 2012
Diffusion Pharmaceuticals LLC, a biotechnology company focused on
innovative cancer treatments, today announced that the U.S. Patent and
Trademark Office has granted it patent numbers 7919527 and 8030350,
entitled "Bipolar Trans Carotenoids Salts and Their Uses" and "Trans
Carotenoids, Their Synthesis and Uses," respectively. These patents
include compound, composition, and methods of use relating to
Diffusion's lead molecule, trans sodium crocetinate (TSC), as
well as the entire family of first-in-class new chemical entities in the
Company's pipeline of therapeutic candidates. Diffusion Pharmaceuticals
is commercializing this family of first-in-class drugs to treat serious
or life-threatening medical conditions characterized by hypoxia or
oxygen deprivation at the cellular level. Enrollment is currently
underway in a multi-center Phase I/II study of TSC for the improved
treatment of newly diagnosed primary brain cancer patients.
"These new patents are important additions to our intellectual property
portfolio, providing strong protection through at least 2027," said
David G. Kalergis, Diffusion's CEO.
Currently the Company has 7 issued U.S. patents, 10 issued foreign
patents and more than 70 pending patent applications filed in all major
international markets.
Source: Diffusion Pharmaceuticals
Urine RNA analysis shows promise for detecting genitourinary diseases